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Hepatitis C virus (HCV) chronically infects 3% of the
world’s population, and complications from HCV are
the leading indication for liver transplantation. Given
the need for better anti-HCV therapies, one strategy
is to identify and target cellular cofactors of the virus
lifecycle.Usinga genome-widesiRNA library,we iden-
tified 96 human genes that support HCV replication,
with a significant number of them being involved in
vesicle organizationandbiogenesis.Phosphatidylino-
sitol 4-kinase PI4KA and multiple subunits of the COPI
vesicle coat complex were among the genes identi-
fied. Consistent with this, pharmacologic inhibitors
of COPI andPI4KAblocked HCV replication. Targeting
hepcidin, a peptide critical for iron homeostasis, also
affected HCV replication, which may explain the
known dysregulation of iron homeostasis in HCV
infection. The host cofactors for HCV replication iden-
tified in this study should serve as a useful resource in
delineating new targets for anti-HCV therapies.
INTRODUCTION
Hepatitis C virus (HCV) is an RNA virus with the remarkable ability
to establish a chronic infection in 70%–80% of exposed humans.
As many as 3% of the world’s population are chronically infected
with HCV. Of that number, as many as 30% will develop cirrhosis
within 20 years of initial infection, which subsequently may lead
to liver failure and/or hepatocellular carcinoma. As a result, HCV-
related liver disease is now the leading indication for liver trans-
plantation worldwide. The best current therapy for chronic HCV
infection is the combination of peginterferon and ribavirin. Unfor-
tunately, these agents are associated with a high rate of side
effects and produce sustained virologic response in only about
half of treated individuals. Although small molecule inhibitors of
the HCV NS3-4A serine protease and NS5B RNA-dependent
RNA polymerase are in clinical development, monotherapy
with direct antiviral agents leads to the rapid emergence of viral
resistance mutations (Reesink et al., 2006) because of the error-
prone nature of the viral RNA polymerase.
Another approach to control HCV is to identify the host cofac-
tors that support the viral lifecycle. Like all viruses, hepatitis C is298 Cell Host & Microbe 5, 298–307, March 19, 2009 ª2009 Elsevierdependent on host proteins for viral entry, uncoating, replication,
virion assembly, and egress. Targeting these cofactors may
impose a higher barrier to viral resistance and also offers the
possibility of blocking the HCV lifecycle at multiple complemen-
tary steps. For instance, a small-molecule inhibitor of cyclophilin
B, which has been shown to interact with and positively regulate
the viral RNA polymerase (Watashi et al., 2005), potently inhibits
HCV replication in vivo (Flisiak et al., 2008). In addition to cyclo-
philin B, to date, a number of other cellular proteins have been
identified as HCV cofactors (Ng et al., 2007; Randall et al.,
2007; Supekova et al., 2008). In this study, we describe the
results of a whole-genome siRNA library screen designed to
identify host proteins that support HCV replication.
RESULTS
Whole-Genome siRNA Screen for Host Cofactors
of HCV Replication
We screened for host proteins involved in HCV replication using
the Huh7/Rep-Feo subgenomic genotype 1b HCV replicon
(Tanabe et al., 2004) that we had previously adapted to high-
throughput screening of small molecule libraries (Kim et al.,
2007). This replicon is an RNA molecule that encodes the HCV
nonstructural proteins (NS3 through NS5B) that are sufficient
to mediate viral replication as well as a firefly luciferase-
neomycin phosphotransferase fusion protein (Figure S1). Firefly
luciferase activity is a linear function of replicon RNA copy
number and therefore permits sensitive and rapid quantitation
of HCV replication (Tanabe et al., 2004). We optimized siRNA
transfection conditions using a luciferase siRNA (Figure S2).
The Huh7/Rep-Feo replicon cell line was then used to screen
a whole-genome siRNA library containing 21,094 siRNA pools
targeting the entire human NCBI RefSeq transcript database.
Each pool is made up of four individual siRNA duplexes, each
directed against a different sequence within the target transcript.
Firefly luciferase activity was measured in duplicate plates, as
was cellular ATP content, as an indicator of cell viability. Figure 1A
depicts the Z scores of the luciferase activities from the duplicate
screening plates across all of the screening pools. A number of
pools that strongly suppressed HCV replication in duplicate wells
can be identified in the lower left quadrant, while very few strongly
discordant values are seen. A complete summary of the whole-
genome screen of all 21,094 pools is given in Table S1.
Using a false discovery rate-based approach for hit selection
(Storey, 2002), we identified 236 pools (1.1% of the library) thatInc.
Figure 1. Bioinformatics of the RNAi Screen
(A) Replicate Z scores from the primary screen. Each point represents the Z score of an individual siRNA pool in one experimental pool plotted against the Z score
of the same pool in the experimental replicate well. A Z score is the number of standard deviations of the experimental luciferase activity above the median plate
value. Negative Z scores indicate inhibition of HCV replication.
(B) Gene ontology biological process terms significantly (p < 0.05) overrepresented by the genes that scored in the screen. The terms are ordered clockwise by
ascending p values.
(C) Functional mapping of HCV dependency factors to lipid- and membrane-related processes that support the formation of a membranous web structure
needed for viral replication. Dotted gray lines indicate protein-protein interactions; dotted blue lines indicate processes that impinge on membranous web struc-
tures; green boxes indicate cellular processes; and black boxes refer to HCV proteins. Supporting references are listed in Table S4.
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significant toxicity. These pools entered the second round of
screening, in which the four component siRNAs in each pool
were individually rescreened. Of these 236 pools, 24 targeting
ribosomal subunits were not evaluated further, as it is known
that the HCV polyprotein is translated by the host translational
machinery (Otto and Puglisi, 2004).
Of the remaining 212 pools, 186 pools (87.7%) had at least one
siRNA decrease HCV replication by : 2 SD compared to a nontar-
geting control siRNA. Ninety-six pools met a threshold of at least
two siRNAs out of four decreasing HCV replication by : 2 SD
(Table S2). We identified only 13 siRNA pools that increased viral
replication with a threshold of q < 0.10 (Table S1); the strongestCell Heffect was only a 2.7-fold increase, and these hits were not
further evaluated.
The 96 HCV cofactors were functionally analyzed using Gene
Ontology (GO) biological process terms. Seventy-nine genes
had at least one GO term associated, and overall, 254 terms
were mapped to these genes. Using a hypergeometric distribu-
tion, 51 terms were significantly (p < 0.05) overrepresented and
mapped to 37 genes. The significant terms were clustered,
and the term with the lowest p value in each cluster was used
to represent that cluster (Table S3). The most significantly
enriched processes were Golgi vesicle binding and vesicle orga-
nization and biogenesis (Figure 1B). Both of these terms included
the six members of the COPI complex.ost & Microbe 5, 298–307, March 19, 2009 ª2009 Elsevier Inc. 299
Cell Host & Microbe
Host Cofactors of Hepatitis C ReplicationTo obtain a more comprehensive view of the processes repre-
sented by the 96 genes, a database framework was created to
integrate information from multiple data sources (see Supple-
mental Data) and the scientific literature to identify the subcel-
lular localization and associated functions of each gene. The
results of this procedure are illustrated in Figures 1C and S3,
with supporting references listed in Table S4. Twenty-seven
genes (28%) were associated with the processes of membrane
biogenesis, sorting, and trafficking. In addition, six genes were
identified as affecting the cellular RNA machinery, including
SERBP1, HNRPAB, and NOP5/NOP58.
There was little overlap between the results of our screen and
three other limited RNAi screens for HCV replication, which
screened 4000 (Ng et al., 2007), 510 (Supekova et al., 2008),
and 62 genes (Randall et al., 2007). We therefore retested 11
siRNA pools (TBXA2R, SLC12A4, SLC12A5, VRK1, CSK1,
JAK1, DDX3X, STAT3, ELAVL1, DICER1, and HSPBP1), which
represented the top hits from each of the prior screens in
Huh7/Rep-Feo cells, and which did not score in our primary
screen (Figure S4). These pools were retested in 96-well format.
Strong (>75%) inhibition of Huh7/Rep-Feo replication was
observed only with TBXA2R silencing. The TBXA2R siRNA
pool did inhibit Huh7/Rep-Feo replication by 43% in the primary
screen (Table S1), though this degree of inhibition did not fall
within the predefined q < 0.10 threshold for secondary
screening. Moderate inhibition (50%–75%) was seen with
CSK, DDX3X, HSPBP1, and SLC12A5 silencing, while < 50%
inhibition was observed with DICER1, ELAVL1, JAK1,
SLC12A4, STAT3, and VRK1 silencing.
Despite the apparent inhibition of HCV replication by siRNAs
targeting SLC12A5, we were unable to identify any expression
of SLC12A5 in Huh7/Rep-Feo cells (data not shown), which is
consistent with prior studies showing that SLC12A5 is
a neuron-specific transcript and is not expressed in the liver
(Payne et al., 1996; Uvarov et al., 2007). This indicates that the
SLC12A5 siRNA pool used by Ng et al. and also used in this
experiment exerts its effect on HCV replication through an off-
target effect.
In addition to the hits discussed below, we retested seven of
our top-ranking hits (CHMP2A,CKAP5,NAPA,RAB7A,RABEPK,
SERBP1, and TRIM62) in the OR6 replicon cell line (Figure S5).
The OR6 replicon contains a full-length genotype 1b HCV
genome and a Renilla luciferase reporter gene (Figure S1), in
contrast to the subgenomic Rep-Feo replicon. These genes
were chosen by inspection from the list of hits based on their
known or proposed roles in membrane trafficking (CHMP2A,
NAPA, RAB7A, RABEPK), in RNA trafficking or translation
(CKAP5, SERBP1), and in the lifecycle of other viruses (TRIM
proteins in HIV infection). All except for TRIM62were reconfirmed
using the criterion of at least two siRNAs causing at least 2-fold
inhibition of HCV replication, though three of the four TRIM62
siRNA duplexes testeddid inhibit OR6 replication by at least 40%.
The PI 4-Kinase PI4KA Is Essential for HCV Replication
A high-ranking hit in our siRNA screen was PI4KA, also known as
PIK4CA or PI4KIIIa. PI4KA encodes a 230 kDa protein and is
widely expressed (Balla et al., 1997); however, the function of
this enzyme in mammalian cells has not been well defined. There
are four known phosphatidylinositol (PI) 4-kinases in mammalian300 Cell Host & Microbe 5, 298–307, March 19, 2009 ª2009 Elseviecells that catalyze the production of PI 4-phosphate from PI (Balla
and Balla, 2006). It has been proposed that the four mammalian
PI 4-kinases have distinct functions that are mediated largely
by their localization to different intracellular compartments
(Balla and Balla, 2006). PI4KA is believed to be predominantly
localized to the ER (Wong et al., 1997), though a fraction may
also be found at the Golgi (Nakagawa et al., 1996).
PI4KA silencing by four individual siRNA duplexes strongly
inhibited HCV replication in the OR6 full-length replicon cell
line (Figure 2A) without detectable cytotoxicity, as determined
by cellular ATP content. PI4KA depletion also strongly inhibited
viral replication in the genotype 2a JFH1 infectious HCV model
(Wakita et al., 2005) by over 2 log10 (Figure 2B). All four siRNA
duplexes depleted PI4KA mRNA transcript levels (Figure 2C);
moreover, siRNA duplex #3 was the most potent for both
PI4KA transcript silencing as well as for inhibition of HCV replica-
tion. Immunoblotting for HCV nonstructural proteins in the OR6
cell line confirmed that PI4KA depletion was associated with
the loss of HCV nonstructural proteins (Figure 2D, lane 3),
comparable to the effect of directly targeting the replicon RNA
with an HCV-specific siRNA (Figure 2D, lane 2).
Two of the four PI 4-kinases, PI4KA and PI4KB, are inhibited
by wortmannin, although at IC50s much higher (50–300 nM)
(Balla and Balla, 2006) than for PI 3-kinases (1–5 nM); no selec-
tive PI 4-kinase inhibitors have been published. The two other PI
4-kinases are wortmannin insensitive. We found that HCV repli-
cation in OR6 replicon cells was inhibited by wortmannin with an
IC50 of 190 nM, which is consistent with the reported IC50 of
PI4KA (Figure 2E) and further demonstrates that PI4KA’s enzy-
matic activity is required for its role in HCV replication. Wortman-
nin treatment at 10 nM, a concentration that effectively inhibits
PI 3-kinases, had no significant effect on HCV replication. There
was no significant cytotoxicity with wortmannin treatment for
24 hr at concentrations up to 1 mM. Moreover, PI4KA silencing
reduced the observed IC50 of wortmannin by over 3-fold
(Figure S6), supporting our hypothesis that wortmannin inhibits
HCV signaling by inhibiting PI4KA activity.
Finally, we generated two independent short hairpin RNA
(shRNA) lentiviral constructs targeting the 30UTR of PI4KA. As
expected, both PI4KA shRNAs blocked HCV replication in OR6
replicon cells, while a nontargeting shRNA had no effect on
HCV replication (Figure 2F). We then generated a shRNA-resis-
tant, full-length PI4KA expression construct lacking the 30UTR
targeted by our shRNA constructs as well as a construct
expressing the other type III PI 4-kinase, PI4KB. Expression of
shRNA-resistant, full-length PI4KA rendered OR6 replicon cells
resistant to both PI4KA shRNAs. However, the effect of silencing
endogenous PI4KA on HCV replication could not be rescued by
exogenous expression of PI4KB, demonstrating that the depen-
dence of HCV on PI4KA is highly specific.
We then sought to ascertain the function of PI4KA in HCV repli-
cation. Given the reported localization of PI4KA to the ER, we
hypothesized that it might have a role in the generation of HCV
nonstructural protein-associated membranes. However, this
hypothesis could not be readily tested in the HCV replicon or
JFH1 infectious viral systems because PI4KA silencing potently
inhibits HCV replication and thus HCV protein expression. There-
fore, we studied the effect of PI4KA silencing on the localization
of HCV nonstructural proteins in the UHCVcon57.3 cell liner Inc.
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Host Cofactors of Hepatitis C ReplicationFigure 2. PI4KA Is Essential for Hepatitis C Virus Replication
(A) PI4KA silencing with four individual siRNA duplexes blocks replication of the full-length HCV replicon OR6 (black bars) without significant cytotoxicity as
measured by cellular ATP content (gray bars). Values were obtained from quadruplicate wells in two independent experiments and are mean ± SD.
(B) siRNAs against PI4KA block replication of the infectious JFH1 HCV strain. Cells were infected with JFH1 48 hr posttransfection, and HCV RNA was quantified
by quantitative PCR (qPCR) at 24 hr postinfection. Values were obtained from triplicate qPCR replicates from duplicate wells and are mean ± SD.
(C)Themagnitude of HCV inhibitionparallels thedegreeofPI4KAsilencing.PI4KA transcripts were quantified by qPCR48 hrposttransfection.Valuesaremean± SD.
(D) PI4KA silencing depletes HCV nonstructural proteins in OR6 replicon cells as determined by immunoblotting with the indicated antibodies. Cell lysates were
prepared from OR6 cells transfected with the indicated siRNAs for 72 hr.
(E) Wortmannin inhibits HCV replication with an IC50 consistent with a type III PI 4-kinase. OR6 replicon cells were treated with the indicated concentrations of wort-
mannin for 24 hr. Replicate wells were assayed for luciferase activity (diamonds) or cellular ATP content (triangles). Values were obtained from quadruplicate wells in
two independent experiments and are mean ± SD.
(F)PI4KAshRNAs block HCV replication and can be rescued by an RNAi-resistant PI4KA construct but not by PI4KB. OR6 replicon cells were transduced with MMLV
retroviral vectors encodingGFP,PI4KA, orPI4KBcDNAs lacking the 30UTR. The cells were then transduced 24 hr later with lentiviral vectors encoding a nontargeting
shRNA (black bars) or two different shRNAs targeting thePI4KA 30UTR (gray and white bars). Cells were assayed 96 hr after lentiviral transduction. Values were ob-
tained from quadruplicate wells in two independent experiments and are mean ± SD.
(G)PI4KA silencing induces the formation of abnormally large NS5A-positive membrane structures. UHCVcon57.3 cells were transduced with the indicated shRNA
constructs 4 days prior to induction of HCV polyprotein expression by withdrawal of tetracycline from the growth medium. Twenty-four hours after induction, cells
were fixed and stained with a monoclonal antibody to HCV NS5A (green) and counterstained with DAPI to highlight cell nuclei (blue).
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Host Cofactors of Hepatitis C ReplicationFigure 3. The COPI Complex Supports HCV Replication Early in the Viral Lifecycle
(A) Individual siRNA duplexes against COPZ1 block replication of the full-length HCV replicon OR6 in a concentration-dependent manner. OR6 cells were trans-
fected with the indicated siRNA duplexes for 64 hr and then assayed for luciferase activity. Values were obtained from quadruplicate wells in two independent
experiments and are mean ± SD.
(B) Individual siRNA duplexes againstCOPZ1 depleteCOPZ1 transcripts in a dose-dependent manner without detectable cytotoxicity. OR6 cells transfected with
the indicated siRNA duplexes as in (A) were assayed for cellular ATP content (open symbols) or for COPZ1 transcript levels by quantitative real-time PCR (closed
symbols). Values were obtained from triplicate qPCR measurements from duplicate wells in two independent experiments and are mean ± SD.
(C) Brefeldin A (BFA), a pharmacologic inhibitor of COPI function, blocks replication of the OR6 full-length replicon. OR6 cells were treated with the indicated
concentrations of BFA for 24 hr and then assayed for luciferase activity (triangles) or cellular ATP content (diamonds). Values were obtained in quadruplicate
and are mean ± SD.
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Host Cofactors of Hepatitis C Replication(Egger et al., 2002), which is stably transformed with a construct
encoding the full-length HCV polyprotein under the control of
a tet-off promoter. Expression of the HCV polyprotein is there-
fore uncoupled from viral replication in this cell line. Induction
of HCV polyprotein expression in cells transduced with a nontar-
geting shRNA results in small punctate membranous structures
that stain positive for HCV NS5A by immunofluorescence
(Figure 2G). However, PI4KA silencing in UHCVcon57.3 cells fol-
lowed by induction of HCV polyprotein expression led to the
formation of abnormally large NS5A-positive structures, indi-
cating that PI4KA is required for the correct formation of the
small membranous structures that have been shown by others
to be the sites of viral RNA replication (Gosert et al., 2003).
The COPI Coat Complex Is Required for Replication
Early in the Viral Lifecycle
The COPI coat is a multisubunit complex composed of the multi-
meric coatomer complex and the ARF GTPase. COPI-coated
vesicles mediate retrograde retrieval of ER-resident proteins
from the Golgi and also play a role in intra-Golgi vesicle traf-
ficking (Be´thune et al., 2006). Six coatomer subunits scored in
the primary siRNA screen (Tables S1–S2). Another high-ranking
hit in the primary screen, CDC42, binds to coatomer via g-COP
(Wu et al., 2000).
We characterized the effect of COPZ1 silencing in further
detail. Four individual siRNA duplexes against COPZ1 all
inhibited HCV replication in the full-length OR6 replicon system
in a concentration-dependent manner (Figure 3A). There was
no cytotoxicity observed under the conditions used in this exper-
iment (Figure 3B), and all four siRNA duplexes depleted COPZ1
mRNA in a concentration-dependent manner. Of note, the
potency of the siRNA duplexes for COPZ1 silencing paralleled
their potency for inhibition of HCV replication.
To further confirm that COPI activity is required for HCV repli-
cation, we employed the pharmacologic COPI inhibitor brefeldin
A (BFA), which blocks COPI coat assembly by inhibiting ARF-
specific guanine nucleotide exchange factors. BFA inhibited
replication of the OR6 full-length replicon in a dose-dependent
fashion, again without measurable cytotoxicity over a 24 hr
period (Figure 3C).
We then examined the ability of BFA to inhibit replication of
the cell-culture-infectious HCV strain JFH1. Consistent with
previous reports (Gastaminza et al., 2008), BFA treatment of
Huh7.5.1 cells that had already been infected for 3 days resulted
in an increase in intracellular viral RNA (Figure 3D). However, in
contrast to the effect of BFA on established HCV infection,
BFA treatment of Huh7.5.1 cells at the time of JFH1 infection
potently inhibited viral replication. BFA effectively inhibited
HCV replication when added at up to 8 hr postinfection, indi-
cating that its effect on blocking HCV replication occurs after
viral entry; maximal internalization and fusion of HCV pseudopar-ticles occur by 3 hr of virus-cell contact (Meertens et al., 2006).
Furthermore, the observed increase in intracellular HCV RNA
when BFA is added in established HCV infection indicates that
the ability of BFA to block HCV replication early in viral infection
is not due to nonspecific cellular toxicity or global inhibition of
RNA synthesis. Immunofluorescence staining of HCV NS5A
and b-COP demonstrated that preformed NS5A-positive struc-
tures in OR6 HCV replicon cells were resistant to short-term
BFA treatment under conditions that induce the rapid dissocia-
tion of COPI from the Golgi complex (Figure 3E), suggesting
that COPI is not actively required for the dynamic maintenance
of established HCV replication complexes as it is for the mainte-
nance of the Golgi complex.
Hepcidin Is a Cofactor for HCV Replication
Hepcidin, encoded by the HAMP (hepcidin antimicrobial
peptide) gene, is a peptide hormone that is a key regulator of
systemic iron homeostasis by inhibiting the iron transporter fer-
roportin (Nemeth et al., 2004b). Chronic HCV infection has long
been recognized to be associated with elevated serum iron
indices as well as with increased hepatic iron stores. This screen
identified an unexpected effect of hepcidin silencing on HCV
replication.
HAMP silencing in the OR6 full-length replicon model by any of
four individual siRNA duplexes or with the HAMP siRNA pool
inhibited HCV replication (Figure 4A) without measurable cyto-
toxicity over 72 hr. We also found that HAMP silencing signifi-
cantly decreased JFH1 replication, though to a lesser magnitude
than in the two replicon systems (Figure 4B). Preliminary studies
using a dicistronic reporter construct to measure HCV IRES-
dependent translation and cap-dependent translation (Itsui
et al., 2006) found inhibition of both IRES- and cap-dependent
translation in HAMP-silenced Huh7 cells (data not shown).
Though this finding remains to be confirmed by additional meth-
odologies, it suggests that HAMP perturbation may affect HCV
replication by altering cellular translation at a more global level
in the hepatocyte.
DISCUSSION
Functional genomic approaches allow for the unbiased identifi-
cation of HCV host cofactors independent of any preconceived
models of the HCV lifecycle or any assumptions about gene
function. This technology has been successfully applied to the
identification of novel host dependency factors for HIV (Brass
et al., 2008). We have conducted a whole-genome RNAi screen
for host proteins that support HCV replication and were able to
functionally confirm the significance of several of these cofactors
in the fully infectious JFH1 HCV strain.
HCV, like other positive-strand RNA viruses, replicates on
altered host membranes, which in the case of HCV have been(D) BFA blocks replication of the infectious JFH1 isolate early in viral infection and blocks HCV secretion late in infection. BFA was added at 100 ng/mL to
Huh7.5.1 cells at the indicated times relative to the time of JFH1 infection. Intracellular HCV RNA was quantified by qPCR at 20 hr of BFA treatment and normal-
ized to HCV RNA from mock treated cells. Values were obtained from triplicate qPCR replicates from duplicate wells and are mean ± SD.
(E) Preformed NS5A-positive structures are resistant to BFA treatment. OR6 cells were treated with 100 mg/mL BFA (lower panels) or 1% ethanol (upper panels)
for 4 hr and then processed for immunofluorescence for HCV NS5A (left panels) and HCV NS5A (middle panels). Nuclei were counterstained with DAPI (blue).
BFA causes dissociation of b-COP from the Golgi apparatus within minutes of treatment.
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Host Cofactors of Hepatitis C ReplicationFigure 4. The Iron Regulatory Hormone Hepcidin Supports HCV Replication
(A) HAMP silencing blocks replication of the full-length HCV replicon OR6. OR6 cells were transfected with the indicated siRNAs for 72 hr and then assayed for
luciferase activity (black bars), HAMP transcript levels (white bars), and cellular ATP content (gray bars). Values were obtained from quadruplicate wells in three
independent experiments and are mean ± SD.
(B) HAMP silencing blocks replication of the infectious JFH1 HCV strain in Huh7 cells. Two-tailed p value was calculated by indepdendent two-sample t test.
Values were obtained from triplicate qPCR replicates from duplicate wells in two independent experiments and are mean ± SD.called ‘‘membranous webs’’ (Egger et al., 2002; Gosert et al.,
2003). The mechanisms by which these membranous webs
form are largely unknown. Here, we identified 27 host genes
that play a role in lipid metabolism, membrane biogenesis,
kinetics, and trafficking; all are likely to be key processes in the
formation and maintenance of the membranous web structure.
PI4KA is an attractive ‘‘druggable’’ target for anti-HCV thera-
peutics. Both genotype 1 and 2 HCV models exhibit a very strong
dependency on PI4KA function; furthermore, PI4KA silencing is
well tolerated in cultured cells. Further evidence that PI4KA
has a direct function in HCV replication comes from a study
(Ahn et al., 2004) that identified an interaction between HCV
NS5A and PI4KA in a yeast two-hybrid screen. The development
of selective PI4KA inhibitors will facilitate the study of this
protein’s cellular function as well as its role in HCV replication,
and it may also yield therapies for chronic HCV infection.
The dependence of HCV replication on the COPI coatomer
complex is shared by poliovirus and Drosophila C virus (Cherry
et al., 2006; Maynell et al., 1992). All three of these RNA viruses
replicate on host membrane-derived compartments, and we
speculate that the assembly of these viral replication compart-
ments is somehow dependent on COPI. Further support for this
hypothesis comes from the finding that g-COP and its interacting
partner, CDC42, are significantly enriched on detergent-insol-
uble membranes from HCV replicon-expressing cells (Mannova´
et al., 2006). These data would suggest that COPI is directly
involved in membranous web formation and that the block of
HCV replication by COPI inhibition is not an indirect effect of dis-
rupting Golgi-ER vesicle trafficking.
Finally, we identified hepcidin as a cofactor for HCV replica-
tion. Chronic hepatitis C infection has long been recognized to
be associated with increased serum iron and transferrin satura-304 Cell Host & Microbe 5, 298–307, March 19, 2009 ª2009 Elsevietion as well as hepatic iron accumulation; moreover, hepatic
hepcidin mRNA expression is increased in patients with chronic
HCV infection (Aoki et al., 2005). Hepcidin transcription is stimu-
lated by iron overload as well as by inflammation through IL-6
(Nemeth et al., 2004a), which is elevated in patients with chronic
HCV. The identification of hepcidin as a HCV replication cofactor
points to a molecular basis for the well-known clinical associa-
tion between chronic HCV infection and dysregulation of iron
homeostasis. Moreover, the potent upregulation of hepcidin
transcription by IL-6 potentially creates a positive feedback
loop between chronic inflammation and HCV replication.
An important limitation of our study is that the replicon model
permits identification of host cofactors of replication but not of
other stages of the viral lifecycle. Future studies using fully infec-
tious, cell-culture-adapted HCV strains will be able to study
other aspects of the HCV lifecycle, such as viral entry, uncoating,
virion assembly, and secretion.
The host cofactors identified in this screen had little overlap
with those identified in three previous limited siRNA screens
for HCV host cofactors (Ng et al., 2007; Randall et al., 2007;
Supekova et al., 2008). Similarly, relatively little overlap has
been observed among the hits in three genome-wide RNAi
screens for HIV host cofactors (Brass et al., 2008; Ko¨nig et al.,
2008; Zhou et al., 2008). There are many factors that must be
considered when comparing our studies with prior limited siRNA
screens. First, the siRNA sequences used in our screen were the
same as for the Ng et al. screen, but were different from those
used in the Supekova et al. and Randall et al. screens, likely
resulting in different knockdown efficiencies and off-target
effects for each gene screened.
Second, the HCV models were different in each screen. Ran-
dall et al. used the J6/JFH1 genotype 2a infectious virus, whiler Inc.
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cons. Silencing of the host protein DDX3X, which binds to the
HCV core protein, suppresses subgenomic HCV replication
much less efficiently than full-length HCV replication (Ariumi
et al., 2007). Furthermore, genotype-specific differences in
host cofactor dependency could also potentially account for
differences in screens using different HCV genotypes.
Third, the methods of siRNA transfection and siRNA concen-
tration and the duration of silencing varied among the screens,
thus biasing the screens toward protein with shorter half-lives
(in the Supekova et al. screen) or longer half-lives (Ng et al.). Ran-
dall et al. tested 62 genes, which is a sufficiently small number
that siRNA could be introduced by electroporation, and the dura-
tion of silencing could be optimized for each gene tested; both
methods are impractical for whole-genome screens.
Fourth and finally, the threshold for identifying significant hits
for secondary validation varied among the different screens.
For example, TBXA2R would have been selected as a hit in our
primary screen had we used the Ng et al. threshold of 30% inhi-
bition. However, using this lower threshold in our screen would
have resulted in over 1800 pools for secondary screening, which
would have been an impractical number of hits for deconvolution.
The strength of whole-genome siRNA screens is their ability to
identify roles for genes and biological pathways in biological
processes free of a priori hypotheses regarding their function.
Our screen has identified many candidate host cofactors for
HCV replication, some of which may offer new therapeutic
avenues for the treatment of chronic infection. Further studies
of these cofactors may yield important mechanistic insights
into the formation and maintenance of the membrane-associ-
ated HCV replication complex. Furthermore, we have identified
a possible molecular link between iron homeostasis, chronic
inflammation, and chronic HCV infection. However, because
of the very significant false-negative (variability in protein
depletion owing to variation in siRNA efficacy and protein half-
life) and false-positive (off-target effects) rates inherent to high-
throughput siRNA screens, no single screen can be expected
to yield a truly comprehensive map of all of the host genes
that are involved in a particular process. Such maps will require




Anti-NS5A (7-D4) and NS3 (9-G2) monoclonal antibodies were obtained from
ViroGen (Cambridge, MA). Anti-b-COP and anti-PI4KA polyclonal antibodies
were obtained from Abcam (Cambridge, MA) and Cell Signaling Technology
(Danvers, MA), respectively. Anti-b-actin monoclonal antibody (AC-74), BFA,
and wortmannin were obtained from Sigma-Aldrich (St. Louis, MO).
siRNA Transfection
siRNA was introduced into Huh7/Rep-Feo cells by reverse transfection using
HiPerFect Transfection Reagent (QIAGEN; Valencia, CA) according to the
manufacturer’s instructions. Nontargeting siRNA and siRNA targeting firefly
luciferase were obtained from QIAGEN and Ambion (Austin, TX), respectively.
siRNA targeting the HCV 50NTR was synthesized according to the si313
sequence (Chevalier et al., 2007). For pilot and validation experiments, control
siRNAs were spotted onto 96- or 384-well plates. HiPerFect was diluted in
Opti-MEM I (Invitrogen; Carlsbad, CA) and then added to the prespotted
siRNAs to allow lipid-siRNA complexes to form. Trypsinized Huh7/Rep-FeoCell Hcells were added to the preformed lipid-siRNA complexes at 5000 cells/well
(96-well format) or 2000 cells/well (384-well format) and then incubated for
72 hr. Firefly luciferase was assayed using Bright-Glo reagent (Promega;
Madison, WI) and a 2103 EnVision Ultra Sensitive Luminescence Plate Reader
(PerkinElmer; Waltham, MA).
High-Throughput Screening
Screening was performed at the Institute of Chemistry and Cell Biology
screening facility at Harvard Medical School. The library used for this screen
was the siARRAY Human Genome siRNA Library (Dharmacon; Lafayette,
CO). Each well in the library contains a pool of four siRNAs designed to target
four different sequences within a single human transcript. All of the unique
human genes in the NCBI RefSeq database are included in this set of
21,094 genes. Each pool is predicted to silence target gene expression at
the mRNA level by at least 75%.
A Bravo Liquid Handling Platform (Velocity11; Menlo Park, CA) was used
to transfer siRNAs from 384-well library stock plates to quadruplicate
screening plates. Diluted HiPerFect was then added to the siRNA with
a WellMate Microplate liquid dispenser (Matrix Technologies; Hudson, NH).
Upon formation of siRNA-lipid complexes, 2000 trypsinized Huh7/Rep-Feo
cells were added to each well. Plates were incubated at 5% CO2, 37C
for 72 hr, whereupon two screening plates were assayed for luciferase
activity using Bright-Glo reagent, and two were assayed for cell viability by
cellular ATP content using CellTiter-Glo reagent (Promega) according to
the manufacturer’s instructions.
Luminescence values were converted to Z scores and then p values (see
Supplemental Data for further details). For hit selection, we used Storey’s false
discovery rate-based approach to multiple-hypothesis testing in order to
control the false-positive error rate without inflating the false-negative error
rate (Storey, 2002). A q value of 0.10, corresponding to a false-discovery
rate of 0.10, was used as the threshold for selecting hit siRNA pools from
the primary screen for siRNA deconvolution. The threshold of 0.10 means
that 10% of the total number of hit pools selected are expected to be false-
positive results. Pools that generated significant cell toxicity (>2-fold decrease
in CellTiter-Glo signal) were rejected, as were pools that targeted ribosomal
subunits or putative transcripts that had been removed by the most recent
RefSeq revision.
The four individual siRNA duplexes comprising each hit siRNA pool were
then individually picked and spotted into separate wells for retesting in the
Huh/Rep-Feo replicon system. Transfection and luminescence assays were
performed exactly as described for the primary screen.
Gene Ontology, Subcellular Localization, and Gene Annotation
Please refer to the Supplemental Data for details on the bioinformatics
methods used.
Secondary Validation in Full-Length HCV Replicon Cells
Selected genes that were associated with HCV replication in Huh7/Rep-Feo
subgenomic replicon cells were tested in OR6 full-length replicon cells
expressing the entire genotype 1b HCV polypeptide downstream of a Renilla
luciferase reporter gene (Ikeda et al., 2005). siRNA duplexes were spotted
into 96-well plates to a final concentration of 50 nM. Diluted HiPerFect Trans-
fection Reagent was added to each well, followed by plating of OR6 cells.
Renilla luciferase activity was normalized to cellular ATP content as deter-
mined by CellTiter-Glo.
JFH1 Infection and Quantitative Real-Time PCR
Infectious genotype 2a JFH1 HCV was prepared as previously described (Wa-
kita et al., 2005). Huh7.5.1 and Huh7 cells were reverse transfected in 96-well
plates with siRNA duplexes under the same conditions as OR6 cells. siRNA-
transfected cells were then infected with JFH1 virus at an moi of 0.2. Total
cellular and viral RNA was isolated postinfection using RNeasy Mini columns
(QIAGEN) with on-column DNase digestion, reverse transcribed by random
priming with the High Capacity cDNA Reverse Transcription Kit (Applied Bio-
systems; Foster City, CA), and then quantitated by real-time PCR using the
DyNAmo HS SYBR Green qPCR kit (Finnzyme; Espoo, Finland). Efficiency-
corrected relative quantitation (Pfaffl, 2001) was used with GAPDH as an
internal control. All primer sequences used are given in Table S5.ost & Microbe 5, 298–307, March 19, 2009 ª2009 Elsevier Inc. 305
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Expression Constructs
shRNAs designed to target the 30UTR of the PI4KA transcript (Table S5) were
cloned into the lentiviral shRNA vector pLKO.1 (Moffat et al., 2006) and
confirmed by sequencing. These constructs or a nontargeting shRNA
construct (pLKO.1-scramble; Addgene; Cambridge, MA) were cotransfected
with the packaging vectors psPAX2 (Addgene plasmid 12260) and pMD2.G
(Addgene plasmid 12259) into 293T cells to generate VSV-G pseudotyped len-
tiviral particles.
Full-length (PI4K230) and truncated (PI4K92) N-terminal myc-tagged PI4KA
constructs in pcDNA3.1/zeo(+) were subcloned into pFB (Stratagene; La Jolla,
CA), a MMLV retroviral vector. VSV-G pseudotyped retroviral particles were
generated by transfection of pFB expression constructs into the 293GPG
packaging cell line (Ory et al., 1996). Lentiviral and retroviral supernatants
were harvested 48 and 72 hr posttransfection, 0.45 mm filtered, and stored
at 80C. Target cells were infected with lentiviral or retroviral particles for
4 hr in the presence of 8 mg/mL polybrene (Sigma).
Immunofluorescence Staining
UHCVcon57.3 cells were plated on gelatin-coated glass coverslips and trans-
duced with a lentiviral vector encoding a nontargeting shRNA or an shRNA
against PI4KA. After induction of HCV polyprotein expression by tetracycline
withdrawal, the cells were fixed with 3% paraformaldehyde, permeabilized
with 0.3% Triton X-100 in PBS, and then blocked with 10% FBS/1% BSA in
PBS with 0.1% Triton X-100. Coverslips were incubated with a NS5A mono-
clonal antibody overnight at 4C, washed, and then incubated with Alexa
594 donkey anti-mouse secondary antibody for 1 hr at RT. Coverslips were
mounted with Fluoromount-G (SouthernBiotech; Birmingham, AL) and viewed
on an epifluorescence microscope.
SUPPLEMENTAL DATA
Supplemental Data include Supplemental Experimental Procedures, Supple-
mental References, six figures, and five tables and can be found online at http://
www.cell.com/cellhostandmicrobe/supplemental/S1931-3128(09)00061-4.
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